Tiziana Life Sciences (AIM:TILS) excellent progress and exciting times ahead.
This biotechnology company, founded in 2013, is focusing on the development of unique therapeutics to target cancer and autoimmune diseases. They have made a number of substantial progressions this year, giving them a positive outlook in targeting currently unmet medical needs.
One of the company’s research priorities is to develop a drug that can target advanced, or ‘metastatic’, breast cancer. This late-stage of the disease is responsible for a huge number of cancer deaths,…
Previous article Next article